TELESIS BIO INC (TBIO) Stock News
NASDAQ:TBIO - Nasdaq - US1920032000 - Common Stock - Currency: USD
TBIO Latest News, Press Relases and Analysis
Regeneron Pharmaceuticals, Inc. (REGN) Licenses Gibson SOLA Platform to Boost R&D Efficiency
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has entered a key licensing agreement with Telesis Bio Inc. to integrate the innovative Gibson SOLA system into its laboratories. This advanced technology allows rapid, in-house DNA and gene synthesis, significantly accelerating REGN’s drug discovery timeline from several weeks to mere hours. By using enzymatic methods to create high-precision DNA and […]
Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis
Mentions: OTC
Telesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA Synthesis
Mentions: OTC
What's Going On With Telesis Bio Shares Thursday?
Telesis Bio shares are moving higher on Thursday after the company announced a partnership with Beckman Coulter Life Sciences.
TBIO Stock Earnings: Telesis Bio Misses EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Telesis Bio (NASDAQ:TBIO) just reported results for the second quarter of 2024....
TBIO Stock Earnings: Telesis Bio Misses EPS, Misses Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Telesis Bio (NASDAQ:TBIO) just reported results for the first quarter of 2024.T...
Telesis Bio Reports First Quarter 2024 Financial Results
Telesis Bio Reports First Quarter 2024 Financial Results...
Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis
Innovation Delivers High-Fidelity, Scalable, Non-Toxic On-Premises Biofoundry Capabilities...
Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis
Innovation Delivers High-Fidelity, Scalable, Non-Toxic On-Premises Biofoundry Capabilities
Telesis Bio Announces Reverse Stock Split
Telesis Bio Announces Reverse Stock Split...
Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market
SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO) (“Telesis” or the “Company”), a leading provider of RNA and DNA solutions...
Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market
TBIO Stock Earnings: Telesis Bio Misses EPS, Misses Revenue for Q2 2024
TBIO stock results show that Telesis Bio missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Telesis Bio Reports Second Quarter and First Half 2024 Financial Results
SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to...
Telesis Bio Reports Second Quarter and First Half 2024 Financial Results
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are a hot topic on Thursday and we have breakdowns of all the latest news affecting shares this morning!
TBIO Stock Earnings: Telesis Bio Misses EPS, Misses Revenue for Q1 2024
TBIO stock results show that Telesis Bio missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Telesis Bio Reports First Quarter 2024 Financial Results